From my friend at AI
# Leronlimab, Maraviroc, and the Potential to Turn “Cold” Tumors “Hot”
### Why CCR5 Blockade Could Become Important in Cancer Treatment
One of the most exciting possibilities for leronlimab is that it may do more than interfere with cancer growth. By blocking the CCR5 receptor, leronlimab may help change the environment surrounding a tumor, potentially allowing the body's immune system to recognize and attack cancer more effectively.
**This is the concept of turning an immunologically “cold” tumor into a “hot” tumor.**
### 1. What Makes a Tumor Cold or Hot?
A **cold tumor** has relatively few active cancer-killing T cells inside it. These tumors often resist immunotherapy because the immune system has difficulty recognizing or attacking the cancer.
A **hot tumor** contains more active immune cells capable of recognizing and attacking cancer cells. These tumors may respond better to checkpoint inhibitors such as Keytruda (pembrolizumab).
Most microsatellite-stable (MSS) metastatic colorectal cancers are relatively resistant to existing checkpoint inhibitors.
### 2. How Leronlimab May Change That
CCR5 is involved in several processes that can help cancer survive, including immune suppression, inflammation, cancer-cell migration, and metastasis.
By blocking CCR5, leronlimab may:
- Reduce signals that recruit tumor-protecting immune cells.
- Change the behavior of macrophages within the tumor environment.
- Potentially improve the ability of cancer-killing T cells to enter tumors.
- Alter PD-L1-related immune signaling.
- Help make certain tumors more responsive to immunotherapy.
These are scientifically plausible mechanisms, but researchers have not yet demonstrated that leronlimab reliably converts cold colorectal tumors into hot tumors in patients.
### 3. Why Leronlimab May Have Advantages Over Maraviroc
Both drugs target CCR5, but they work differently.
**Maraviroc** is an oral small-molecule drug that binds within a pocket of the CCR5 receptor, changing its shape and interfering with receptor signaling.
**Leronlimab** is a monoclonal antibody that binds to the receptor's external surface, interfering with certain CCR5-mediated interactions.
Leronlimab may offer sustained receptor blockade, which could be useful in cancer treatment. However, no head-to-head clinical trial has established that leronlimab is superior to maraviroc for treating cancer.
Combining the two drugs is also not necessarily more effective than using either one alone. Because both target CCR5, researchers would need to demonstrate that the combination provides additional benefit.
### 4. The PD-L1 and Keytruda Connection
One particularly interesting possibility is that leronlimab could help prepare tumors for immune checkpoint inhibitors.
Cancer cells can use the PD-1/PD-L1 pathway to suppress immune attacks. Keytruda blocks PD-1, helping certain immune cells maintain their anticancer activity.
If leronlimab changes the tumor's immune environment and increases effective T-cell activity, Keytruda may have a better opportunity to work.
**The potential strategy is to use leronlimab to help make the tumor more immunologically responsive, then use checkpoint inhibition to support the immune attack.**
Importantly, increased PD-L1 expression alone does not prove that a cold tumor has become hot. Researchers must also demonstrate meaningful changes in immune-cell infiltration, immune activation, and clinical outcomes.
### 5. Why CytoDyn's CLOVER Trial Matters
CytoDyn's CLOVER trial combines leronlimab with TAS-102 and bevacizumab in metastatic colorectal cancer.
Reported findings from 2026 include:
- CCR5 expression in all 91 evaluable prescreening tumor samples.
- An 86% median reduction in circulating tumor DNA at Week 2 among 28 evaluable patients, according to CytoDyn's October 2026 update.
- Earlier observations of increased PD-L1 expression in certain circulating tumor-associated cells.
These findings are encouraging and support continued investigation of CCR5 blockade.
However, circulating tumor DNA reductions are not equivalent to confirmed tumor responses, and the three-drug combination makes it difficult to determine how much of the observed activity is attributable specifically to leronlimab.
### 6. What Would Demonstrate That Cold Tumors Are Becoming Hot?
Researchers would ideally establish three things:
1. **Tumor biopsy evidence:** More active CD8+ cancer-killing T cells entering tumors after treatment.
2. **Improved immunotherapy responses:** Confirmed tumor shrinkage when leronlimab is combined with checkpoint inhibitors, particularly in MSS colorectal cancer.
3. **Durable clinical benefit:** Longer progression-free survival and overall survival compared with an appropriate control group.
If these findings emerge together, they would provide stronger evidence that leronlimab can meaningfully change the tumor immune environment.
### 7. The Bigger Opportunity for Leronlimab
The most exciting possibility may not be combining leronlimab with another CCR5 inhibitor such as maraviroc.
Instead, it may be using leronlimab to make existing cancer treatments more effective.
Chemotherapy attacks cancer cells directly. Bevacizumab interferes with tumor blood-vessel signaling. Checkpoint inhibitors help immune cells overcome certain suppressive signals.
Leronlimab could potentially complement these treatments by interfering with CCR5-related pathways that help tumors survive and resist immune attacks.
**If leronlimab can help convert resistant, immune-cold tumors into immune-active tumors that respond durably to checkpoint inhibitors, it could represent an important advance in cancer treatment.**
That possibility remains unproven, but it provides a compelling scientific rationale for further clinical investigation.
### Final Thoughts
The early CLOVER findings make CCR5 an interesting therapeutic target and leronlimab a drug worth following closely.
The critical questions now concern confirmed tumor responses, durability, survival, and whether immune changes observed in laboratory measurements translate into meaningful benefits for patients.
**The greatest potential of leronlimab may be its ability to help the immune system become a more effective partner in fighting cancer.**
If future controlled clinical trials demonstrate that capability, the implications could extend beyond colorectal cancer into other difficult-to-treat solid tumors.
*Scientific perspective based on reported 2026 CytoDyn findings and established CCR5 biology. Leronlimab remains investigational and is not an FDA-approved cancer treatment.*
# Leronlimab, Maraviroc, and the Potential to Turn “Cold” Tumors “Hot”
### Why CCR5 Blockade Could Become Important in Cancer Treatment
One of the most exciting possibilities for leronlimab is that it may do more than interfere with cancer growth. By blocking the CCR5 receptor, leronlimab may help change the environment surrounding a tumor, potentially allowing the body's immune system to recognize and attack cancer more effectively.
**This is the concept of turning an immunologically “cold” tumor into a “hot” tumor.**
### 1. What Makes a Tumor Cold or Hot?
A **cold tumor** has relatively few active cancer-killing T cells inside it. These tumors often resist immunotherapy because the immune system has difficulty recognizing or attacking the cancer.
A **hot tumor** contains more active immune cells capable of recognizing and attacking cancer cells. These tumors may respond better to checkpoint inhibitors such as Keytruda (pembrolizumab).
Most microsatellite-stable (MSS) metastatic colorectal cancers are relatively resistant to existing checkpoint inhibitors.
### 2. How Leronlimab May Change That
CCR5 is involved in several processes that can help cancer survive, including immune suppression, inflammation, cancer-cell migration, and metastasis.
By blocking CCR5, leronlimab may:
- Reduce signals that recruit tumor-protecting immune cells.
- Change the behavior of macrophages within the tumor environment.
- Potentially improve the ability of cancer-killing T cells to enter tumors.
- Alter PD-L1-related immune signaling.
- Help make certain tumors more responsive to immunotherapy.
These are scientifically plausible mechanisms, but researchers have not yet demonstrated that leronlimab reliably converts cold colorectal tumors into hot tumors in patients.
### 3. Why Leronlimab May Have Advantages Over Maraviroc
Both drugs target CCR5, but they work differently.
**Maraviroc** is an oral small-molecule drug that binds within a pocket of the CCR5 receptor, changing its shape and interfering with receptor signaling.
**Leronlimab** is a monoclonal antibody that binds to the receptor's external surface, interfering with certain CCR5-mediated interactions.
Leronlimab may offer sustained receptor blockade, which could be useful in cancer treatment. However, no head-to-head clinical trial has established that leronlimab is superior to maraviroc for treating cancer.
Combining the two drugs is also not necessarily more effective than using either one alone. Because both target CCR5, researchers would need to demonstrate that the combination provides additional benefit.
### 4. The PD-L1 and Keytruda Connection
One particularly interesting possibility is that leronlimab could help prepare tumors for immune checkpoint inhibitors.
Cancer cells can use the PD-1/PD-L1 pathway to suppress immune attacks. Keytruda blocks PD-1, helping certain immune cells maintain their anticancer activity.
If leronlimab changes the tumor's immune environment and increases effective T-cell activity, Keytruda may have a better opportunity to work.
**The potential strategy is to use leronlimab to help make the tumor more immunologically responsive, then use checkpoint inhibition to support the immune attack.**
Importantly, increased PD-L1 expression alone does not prove that a cold tumor has become hot. Researchers must also demonstrate meaningful changes in immune-cell infiltration, immune activation, and clinical outcomes.
### 5. Why CytoDyn's CLOVER Trial Matters
CytoDyn's CLOVER trial combines leronlimab with TAS-102 and bevacizumab in metastatic colorectal cancer.
Reported findings from 2026 include:
- CCR5 expression in all 91 evaluable prescreening tumor samples.
- An 86% median reduction in circulating tumor DNA at Week 2 among 28 evaluable patients, according to CytoDyn's October 2026 update.
- Earlier observations of increased PD-L1 expression in certain circulating tumor-associated cells.
These findings are encouraging and support continued investigation of CCR5 blockade.
However, circulating tumor DNA reductions are not equivalent to confirmed tumor responses, and the three-drug combination makes it difficult to determine how much of the observed activity is attributable specifically to leronlimab.
### 6. What Would Demonstrate That Cold Tumors Are Becoming Hot?
Researchers would ideally establish three things:
1. **Tumor biopsy evidence:** More active CD8+ cancer-killing T cells entering tumors after treatment.
2. **Improved immunotherapy responses:** Confirmed tumor shrinkage when leronlimab is combined with checkpoint inhibitors, particularly in MSS colorectal cancer.
3. **Durable clinical benefit:** Longer progression-free survival and overall survival compared with an appropriate control group.
If these findings emerge together, they would provide stronger evidence that leronlimab can meaningfully change the tumor immune environment.
### 7. The Bigger Opportunity for Leronlimab
The most exciting possibility may not be combining leronlimab with another CCR5 inhibitor such as maraviroc.
Instead, it may be using leronlimab to make existing cancer treatments more effective.
Chemotherapy attacks cancer cells directly. Bevacizumab interferes with tumor blood-vessel signaling. Checkpoint inhibitors help immune cells overcome certain suppressive signals.
Leronlimab could potentially complement these treatments by interfering with CCR5-related pathways that help tumors survive and resist immune attacks.
**If leronlimab can help convert resistant, immune-cold tumors into immune-active tumors that respond durably to checkpoint inhibitors, it could represent an important advance in cancer treatment.**
That possibility remains unproven, but it provides a compelling scientific rationale for further clinical investigation.
### Final Thoughts
The early CLOVER findings make CCR5 an interesting therapeutic target and leronlimab a drug worth following closely.
The critical questions now concern confirmed tumor responses, durability, survival, and whether immune changes observed in laboratory measurements translate into meaningful benefits for patients.
**The greatest potential of leronlimab may be its ability to help the immune system become a more effective partner in fighting cancer.**
If future controlled clinical trials demonstrate that capability, the implications could extend beyond colorectal cancer into other difficult-to-treat solid tumors.
*Scientific perspective based on reported 2026 CytoDyn findings and established CCR5 biology. Leronlimab remains investigational and is not an FDA-approved cancer treatment.*
5
